Could ongoing trials redefine the management of oligometastatic and advanced prostate cancer? In this installment of BackTable Tumor Board, leading prostate cancer experts Dr. Neeraj Agarwal, a medical oncologist from the University of Utah, and Dr. Tyler Seibert, a radiation oncologist from UC San Diego, join host Dr. Parth Modi to share their insights on the latest clinical trials and persistent challenges in managing prostate cancer.

---

This podcast is supported by:
Ferring Pharmaceuticals

---

SYNPOSIS

The multidisciplinary discussion addresses clinical decision-making in active surveillance versus early intervention, the role of PSMA PET imaging in detection and treatment planning, and evolving strategies for metastatic and castration-resistant disease. They also evaluate the therapeutic potential of alpha emitters and radioligand therapies, consider the evidence behind treatment intensification and de-intensification, and explore how these approaches can be individualized to optimize patient outcomes.

---

TIMESTAMPS

0:00 - Introduction
1:48 - Active Surveillance in Low-Risk Prostate Cancer
7:08 - Molecular Testing and Risk Stratification
8:28 - Radiation Therapy Approaches
20:16 - PSA Recurrence and PSMA PET Scans
32:40 - The Role of ADT
37:15 - PSMA PET Scans
40:58 - Genetic Testing in High-Risk and Metastatic Prostate Cancer
46:54 - Treatment Intensification vs. De-Intensification Trials
55:59 - Castration-Resistant Prostate Cancer

Ep. 259 Prostate Tumor Board: Risk Stratification & Treatment Strategies with Dr. Neeraj Agarwal and Dr. Tyler Seibert

Powered by Wave AI